Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $18.75 Consensus Price Target from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.75.

Several research analysts have recently issued reports on ATRA shares. RODMAN&RENSHAW raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Canaccord Genuity Group upped their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th.

Atara Biotherapeutics Stock Down 1.9 %

Atara Biotherapeutics stock opened at $16.53 on Tuesday. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50. The firm has a market capitalization of $95.21 million, a price-to-earnings ratio of -0.64 and a beta of 0.51. The firm has a 50-day moving average price of $12.20 and a two-hundred day moving average price of $9.78.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the firm posted ($16.50) earnings per share. Research analysts expect that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics in the second quarter worth approximately $53,000. FMR LLC increased its holdings in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Atara Biotherapeutics by 11.3% during the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 12,677 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.